Media headlines about Biogen (NASDAQ:BIIB) have trended positive this week, according to Alpha One Sentiment Analysis. Alpha One, a unit of Accern, identifies negative and positive news coverage by reviewing more than twenty million news and blog sources. Alpha One ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Biogen earned a coverage optimism score of 0.26 on Alpha One’s scale. Alpha One also assigned news coverage about the biotechnology company an impact score of 73 out of 100, meaning that recent news coverage is likely to have an impact on the stock’s share price in the immediate future.

These are some of the media stories that may have effected AlphaOne Sentiment’s scoring:

Insider Buying and Selling by Quarter for Biogen (NASDAQ:BIIB)

Shares of Biogen (BIIB) traded down 1.29% during mid-day trading on Friday, reaching $251.74. The company’s stock had a trading volume of 2,427,665 shares. Biogen has a 12 month low of $223.02 and a 12 month high of $333.65. The stock has a market capitalization of $53.40 billion, a P/E ratio of 15.77 and a beta of 0.83. The company has a 50 day moving average price of $257.29 and a 200 day moving average price of $276.02.

Biogen (NASDAQ:BIIB) last released its earnings results on Tuesday, April 25th. The biotechnology company reported $5.20 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.97 by $0.23. Biogen had a net margin of 30.17% and a return on equity of 38.17%. The business had revenue of $2.81 billion during the quarter, compared to analysts’ expectations of $2.73 billion. During the same quarter last year, the company earned $4.79 earnings per share. The firm’s revenue was up 3.1% on a year-over-year basis. On average, equities research analysts anticipate that Biogen will post $20.48 earnings per share for the current fiscal year.

BIIB has been the subject of a number of research reports. Leerink Swann downgraded Biogen from an “outperform” rating to a “market perform” rating and set a $300.00 price target for the company. in a research report on Thursday, March 16th. Vetr raised Biogen from a “buy” rating to a “strong-buy” rating and set a $310.17 price target for the company in a research report on Monday, March 20th. TheStreet raised Biogen from a “c+” rating to a “b-” rating in a research report on Tuesday, February 21st. Mizuho lowered their price target on Biogen from $290.00 to $274.00 and set a “neutral” rating for the company in a research report on Wednesday, May 31st. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $277.00 price target on shares of Biogen in a research report on Thursday, May 25th. Twelve investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. Biogen currently has a consensus rating of “Buy” and an average price target of $330.18.

COPYRIGHT VIOLATION WARNING: “Biogen (BIIB) Given Daily Media Impact Rating of 0.26” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at

In related news, Director Brian S. Posner sold 1,084 shares of the stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $256.31, for a total value of $277,840.04. Following the completion of the sale, the director now owns 6,330 shares in the company, valued at $1,622,442.30. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Michel Vounatsos bought 1,402 shares of Biogen stock in a transaction that occurred on Monday, May 1st. The stock was bought at an average price of $271.35 per share, with a total value of $380,432.70. The disclosure for this purchase can be found here. In the last quarter, insiders sold 12,957 shares of company stock valued at $3,689,473. 0.32% of the stock is owned by corporate insiders.

About Biogen

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Receive News & Stock Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related stocks with our FREE daily email newsletter.